Search people, articles, bills, and more
Voters should care about this bill because it aims to tackle the high cost of prescription drugs, a persistent concern for many Americans. When brand-name drug manufacturers use tactics to delay the approval of generic or biosimilar versions, it keeps drug prices artificially high, forcing consumers and insurance companies to pay more for essential medications.
If this bill becomes law, it could lead to quicker availability of more affordable generic and biosimilar drugs, potentially saving patients money and increasing competition in the pharmaceutical market. If it doesn't pass, the current system allowing for potentially abusive citizen petitions would continue, which critics argue allows brand-name drug manufacturers to extend their monopolies and maintain high prices, impacting healthcare affordability for everyone.
No reactions yet. Be the first to weigh in.
Voters should care about this bill because it aims to tackle the high cost of prescription drugs, a persistent concern for many Americans. When brand-name drug manufacturers use tactics to delay the approval of generic or biosimilar versions, it keeps drug prices artificially high, forcing consumers and insurance companies to pay more for essential medications.
If this bill becomes law, it could lead to quicker availability of more affordable generic and biosimilar drugs, potentially saving patients money and increasing competition in the pharmaceutical market. If it doesn't pass, the current system allowing for potentially abusive citizen petitions would continue, which critics argue allows brand-name drug manufacturers to extend their monopolies and maintain high prices, impacting healthcare affordability for everyone.
An AI model extracted this from the bill’s official record and can make mistakes. Check the official text ↗ (opens in new tab)
An AI model extracted this from the bill’s official record and can make mistakes. Check the official text ↗ (opens in new tab)
| TYPE | AMOUNT | WHO |
|---|---|---|
| civil | The greater of: (A) revenue earned from the sale of any drug product referenced in a covered application that was the subject of a sham petition during the review period, OR (B) $50,000 for each calendar day that each sham petition or series of sham petitions was under review. | Any person found liable for submitting or causing the submission of a sham petition or series of petitions. |